Reata Pharmaceuticals Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Reata Pharmaceuticals stock.
View analyst ratings for Reata Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Reata Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Reata Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Reata Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Reata Pharmaceuticals.

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) announced its quarterly earnings results on Thursday, May, 6th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($2.18) by $0.32. The firm earned $0.94 million during the quarter, compared to analyst estimates of $1.43 million. Reata Pharmaceuticals had a negative trailing twelve-month return on equity of 88.44% and a negative net margin of 3,092.54%. The company's quarterly revenue was down 30.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.89) EPS.
View Reata Pharmaceuticals' earnings history.

Reata Pharmaceuticals' stock was trading at $157.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RETA stock has decreased by 18.9% and is now trading at $128.06.
View which stocks have been most impacted by COVID-19.

4 equities research analysts have issued twelve-month target prices for Reata Pharmaceuticals' shares. Their forecasts range from $155.00 to $244.00. On average, they expect Reata Pharmaceuticals' stock price to reach $219.00 in the next year. This suggests a possible upside of 71.0% from the stock's current price.
View analysts' price targets for Reata Pharmaceuticals or view top-rated stocks among Wall Street analysts.

10 employees have rated Reata Pharmaceuticals CEO Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among Reata Pharmaceuticals' employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Reata Pharmaceuticals include Elanco Animal Health (ELAN), Viatris (VTRS), BioMarin Pharmaceutical (BMRN), Zai Lab (ZLAB), Ono Pharmaceutical (OPHLF), Maravai LifeSciences (MRVI), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Grifols (GRFS), Dr. Reddy's Laboratories (RDY), Jazz Pharmaceuticals (JAZZ), CureVac (CVAC), United Therapeutics (UTHR), Mirati Therapeutics (MRTX) and Biohaven Pharmaceutical (BHVN).
View all of RETA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

(RETA) raised $60 million in an IPO on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Reata Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Emerald Advisers LLC (0.68%) and Eagle Global Advisors LLC (0.09%). Company insiders that own Reata Pharmaceuticals stock include Colin John Meyer, Elaine Castellanos, James W Traweek Jr, James Warren Huff, Jason Douglas Wilson and Michael D Wortley.
View institutional ownership trends for Reata Pharmaceuticals.

RETA stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Colin John Meyer, Elaine Castellanos, James Warren Huff, and Michael D Wortley.
View insider buying and selling activity for Reata Pharmaceuticals or view top insider-selling stocks.

RETA stock was purchased by a variety of institutional investors in the last quarter, including Eagle Global Advisors LLC.
View insider buying and selling activity for Reata Pharmaceuticals or or view top insider-buying stocks.

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RETA stock can currently be purchased for approximately $128.06.

Reata Pharmaceuticals has a market capitalization of $4.65 billion and generates $9.02 million in revenue each year. The company earns $-247,750,000.00 in net income (profit) each year or ($7.35) on an earnings per share basis.

Reata Pharmaceuticals employs 267 workers across the globe.

The official website for Reata Pharmaceuticals is www.reatapharma.com.

Reata Pharmaceuticals is headquartered at 5320 LEGACY DRIVE, PLANO TX, 75024.

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The company can be reached via phone at (972) 865-2219 or via email at [email protected]